Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter G Parsons

Showing results (61-70 of 71) with videos related to

Pageof 8
Sort By:
Scientific Reports|September 27, 2016
Expression profiling of cutaneous squamous cell carcinoma with perineural invasion implicates the p53 pathway in the processTimothy A Warren, Natasa Broit, Jacinta L Simmons, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 23, 2006
Neutrophils are a key component of the antitumor efficacy of topical chemotherapy with ingenol-3-angelateJodie M Challacombe, Andreas Suhrbier, Peter G Parsons, et al.
Chemistry (Weinheim an Der Bergstrasse, Germany)|September 29, 2020
Synthetic Tigliane Intermediates Engage Thiols to Induce Potent Cell Line Selective Anti-Cancer ActivitySharon Chow, Tanja Krainz, Christian J Bettencourt, et al.
Chemistry (Weinheim an Der Bergstrasse, Germany)|September 1, 2020
EBC-232 and 323: A Structural Conundrum Necessitating Unification of Five In Silico Prediction and Elucidation MethodsLidia A Maslovskaya, Andrei I Savchenko, Elizabeth H Krenske, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 11, 2007
Nuclear targeting of the growth hormone receptor results in dysregulation of cell proliferation and tumorigenesisBecky L Conway-Campbell, Jong Wei Wooh, Andrew J Brooks, et al.
Cancer Research|April 17, 2004
Antitumor activity of 3-ingenyl angelate: plasma membrane and mitochondrial disruption and necrotic cell deathSteven M Ogbourne, Andreas Suhrbier, Brad Jones, et al.
Scientific Reports|January 9, 2021
Activation of PKC supports the anticancer activity of tigilanol tiglate and related epoxytiglianesJason K Cullen, Glen M Boyle, Pei-Yi Yap, et al.
Oncogene|March 30, 2004
Microarray expression profiling in melanoma reveals a BRAF mutation signatureSandra Pavey, Peter Johansson, Leisl Packer, et al.
Science Translational Medicine|September 14, 2022
Topical, immunomodulatory epoxy-tiglianes induce biofilm disruption and healing in acute and chronic skin woundsLydia C Powell, Jason K Cullen, Glen M Boyle, et al.
Journal for Immunotherapy of Cancer|April 24, 2024
Tigilanol tiglate is an oncolytic small molecule that induces immunogenic cell death and enhances the response of both target and non-injected tumors to immune checkpoint blockadeJason K Cullen, Pei-Yi Yap, Blake Ferguson, et al.
Pageof 8

Showing results (61-70 of 71) with videos related to

Sort By:
Pageof 8
Scientific Reports|September 27, 2016
Expression profiling of cutaneous squamous cell carcinoma with perineural invasion implicates the p53 pathway in the processTimothy A Warren, Natasa Broit, Jacinta L Simmons, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 23, 2006
Neutrophils are a key component of the antitumor efficacy of topical chemotherapy with ingenol-3-angelateJodie M Challacombe, Andreas Suhrbier, Peter G Parsons, et al.
Chemistry (Weinheim an Der Bergstrasse, Germany)|September 29, 2020
Synthetic Tigliane Intermediates Engage Thiols to Induce Potent Cell Line Selective Anti-Cancer ActivitySharon Chow, Tanja Krainz, Christian J Bettencourt, et al.
Chemistry (Weinheim an Der Bergstrasse, Germany)|September 1, 2020
EBC-232 and 323: A Structural Conundrum Necessitating Unification of Five In Silico Prediction and Elucidation MethodsLidia A Maslovskaya, Andrei I Savchenko, Elizabeth H Krenske, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 11, 2007
Nuclear targeting of the growth hormone receptor results in dysregulation of cell proliferation and tumorigenesisBecky L Conway-Campbell, Jong Wei Wooh, Andrew J Brooks, et al.
Cancer Research|April 17, 2004
Antitumor activity of 3-ingenyl angelate: plasma membrane and mitochondrial disruption and necrotic cell deathSteven M Ogbourne, Andreas Suhrbier, Brad Jones, et al.
Scientific Reports|January 9, 2021
Activation of PKC supports the anticancer activity of tigilanol tiglate and related epoxytiglianesJason K Cullen, Glen M Boyle, Pei-Yi Yap, et al.
Oncogene|March 30, 2004
Microarray expression profiling in melanoma reveals a BRAF mutation signatureSandra Pavey, Peter Johansson, Leisl Packer, et al.
Science Translational Medicine|September 14, 2022
Topical, immunomodulatory epoxy-tiglianes induce biofilm disruption and healing in acute and chronic skin woundsLydia C Powell, Jason K Cullen, Glen M Boyle, et al.
Journal for Immunotherapy of Cancer|April 24, 2024
Tigilanol tiglate is an oncolytic small molecule that induces immunogenic cell death and enhances the response of both target and non-injected tumors to immune checkpoint blockadeJason K Cullen, Pei-Yi Yap, Blake Ferguson, et al.
Pageof 8